- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01083199
Global Performance Evaluation of the AMS CONTINUUM™ Device
Global Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
- To evaluate Device performance in providing mucosa to mucosa apposition to facilitate sustainable vesico-urethral anastomosis during a radical prostatectomy procedure.
- To assess clinical outcomes of the Device in facilitating the vesico-urethral anastomosis following a radical prostatectomy.
Studienübersicht
Detaillierte Beschreibung
Radical prostatectomy (RP) is the most utilized surgical treatment option for localized prostate cancer due to the multi-focal nature of the disease. RP is most suitable for otherwise healthy men whose cancer is limited to a small area. The RP procedure involves removing the prostate gland, seminal vesicles and nearby lymph nodes. One of the most technically challenging and critical aspects in all of these surgical approaches is reconstruction of the interrupted urinary tract by hand sewing the vesico-urethral anastomosis. This is where the bladder neck is sewn to the urethra after the prostate has been removed.
CONTINUUM™ (study Device) is to be used as part of the RP procedure by facilitating the approximation of the bladder neck and urethral stump. The Device brings together and holds the tissue in place until adequate natural healing of the vesico-urethral anastomosis occurs thereby minimizing extravasation. The Device also provides a conduit for drainage of urine from the bladder out the urethra during tissue healing.
The concept of the CONTINUUM™ device and the feasibility of its operation have been successfully tested in animal and human studies. Pilot clinical studies in the United States (G060095) found that the majority of subjects who received and were discharged with the Device demonstrated a water-tight vesico-urethral anastomosis at the first Device removal visit. Additionally, no unanticipated adverse device effects (UADEs) were reported. The focus of the proposed study is to further verify the performance of the Device in global research centers.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
-
Rio-Patras, Griechenland, 26500
- University of Patras
-
-
-
-
-
Madrid, Spanien, 28007
- Hospital University Gregorio Maranon
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- All males ≥ 40 years old who are indicated for a radical prostatectomy will be eligible to participate in the study
Exclusion Criteria:
- If contraindicated for surgery
- Inability to understand the study or a history of non-compliance with medical advice
- Unwilling or unable to sign an Informed Consent Form (ICF)
A history of:
- Recurrent urinary tract infections (UTI)
- Recurrent stricture disease
- Neurological disease with a history of bladder dysfunction (e.g., Parkinson's disease)
- Uncontrolled insulin-dependent diabetes
- Chemotherapy within the past 6 months
- Non-topical steroid use within the past 6 months
- Allergy to nitinol, nickel, titanium or silicone
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: CONTINUUMTM
|
Leistung von CONTINUUM™ bei der Erleichterung der vesiko-urethralen Anastomose nach radikaler Prostatektomie.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Successful Device Placement
Zeitfenster: During Radical Prostatectomy
|
Successful Device placement was defined as the establishment of a water-tight anastomosis immediately post-Device placement.
|
During Radical Prostatectomy
|
Functionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-procedure in Subjects With Successful Device Placement
Zeitfenster: 7-21 days post-Device placement
|
Device removal was first attempted at the 7-day window; if extravasation was noted, the subject returned for a second attempt at the 14-day window. If extravasation was noted at the first and second attempts, the subject could then return for a 3rd and final removal at the 21-day window. The following defines the timeframe of each removal attempt:
|
7-21 days post-Device placement
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Intraoperative/Postoperative Parameters
Zeitfenster: At Device placement
|
At Device placement
|
Percentage of Subjects Demonstrating Functionally Adequate Anastomosis at the 1st and 2nd Device Removal Visits
Zeitfenster: 7 and 14 days post-Device placement
|
7 and 14 days post-Device placement
|
Incontinence Rate and I-QOL Score
Zeitfenster: Baseline, 6-week, 6 and 12-month evaluations
|
Baseline, 6-week, 6 and 12-month evaluations
|
Bladder Neck Contracture (BNC) Rate
Zeitfenster: Subjects that develop BNC between the scheduled follow-up visits at 6 weeks, 6 and 12 months post-device removal
|
Subjects that develop BNC between the scheduled follow-up visits at 6 weeks, 6 and 12 months post-device removal
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Evangelos Liatsikos, MD, University of Patras
- Hauptermittler: Carlos Hernandez, MD, Hospital University Gregorio Maranon
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- PE0702
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur KONTINUUM™
-
Stanford UniversityBill and Melinda Gates FoundationAbgeschlossenKind | Schwangerschaft | Kleinkind | Ernährung | Die Gesundheit
-
Institut de cancérologie Strasbourg EuropeContinuum Plus Santé; Plateforme nationale qualité de vie et cancer; WeShareRekrutierungNeoplasien der Brust | Lungentumoren | Prostataneoplasmen | Kolorektale NeubildungenFrankreich
-
Massachusetts General HospitalAbgeschlossenFortgeschrittener Krebs | Häusliche Pflege, krankenhausbasiertVereinigte Staaten
-
BaroNova, Inc.AbgeschlossenFettleibigkeitAustralien
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive MedicalUnbekanntHirnschaden, chronisch | Cerebellar Cognitive Affective Syndrome | Kleinhirn-Mutismus
-
Boston Scientific CorporationAbgeschlossenTransitorische ischämische Attacke | Thromboembolischer Schlaganfall | Schlaganfall-PräventionVereinigte Staaten, Argentinien, Deutschland
-
Gülçin Özalp GerçekerAbgeschlossenKatheterkomplikationen | KatheterleckageTruthahn
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting, Inc.RekrutierungHydrozephalus | Hydrozephalus, KommunizierenArgentinien
-
Medtronic CardiovascularMedtronicAbgeschlossenAortenstenoseNeuseeland, Vereinigtes Königreich, Australien
-
Andrew ParrentUniversity of Western Ontario, Canada; Synaptive MedicalUnbekanntTemporallappenepilepsie